IL-36 family cytokines in protective versus destructive inflammation.


Journal

Cellular signalling
ISSN: 1873-3913
Titre abrégé: Cell Signal
Pays: England
ID NLM: 8904683

Informations de publication

Date de publication:
11 2020
Historique:
received: 31 07 2020
revised: 01 09 2020
accepted: 02 09 2020
pubmed: 9 9 2020
medline: 21 10 2021
entrez: 8 9 2020
Statut: ppublish

Résumé

The IL-1 family of cytokines and receptors are critical regulators of inflammation. Within the IL-1 family and in contrast to its IL-1 and IL-18 subfamilies, the IL-36 subfamily is still poorly characterized. Three pro-inflammatory agonists IL-36α, IL-36β, IL-36γ, one IL-36 receptor (IL-1R6) antagonist, IL-36RA, and one putative IL-1R6 antagonist, IL-38, have been grouped into the IL-36 cytokine subfamily. IL-36 agonists signal through a common receptor complex to serve as early triggers of inflammatory responses by activating and cross-regulating a number of inflammatory pathways including NF-κB, MAPK and IFN signaling. IL-36RA binds to IL-1R6 to limit inflammatory signaling, while IL-38 may be an antagonist of more than one IL-1 family receptor. Expression patterns of IL-36 family cytokines, being most prominently expressed in epithelial barrier tissues such as the skin and intestines as well as in immune cells, suggest a role in protecting these barriers from infection. Dysregulation of IL-36 family cytokine signaling at physiological barriers, most prominently the skin, induces autoimmune inflammation. However, transferring the potential of IL-36 to induce tissue damage to tumors might benefit cancer patients. Here we summarize signaling pathways regulated by IL-36 family cytokines, including IL-38, and the consequences for physiological protective and pathophysiological destructive inflammation. Moreover, we discuss the limits of current knowledge on IL-36 family function to open potential avenues for research in the future.

Identifiants

pubmed: 32898612
pii: S0898-6568(20)30250-3
doi: 10.1016/j.cellsig.2020.109773
pii:
doi:

Substances chimiques

Interleukin-1 0
NF-kappa B 0
interleukin 36, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

109773

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflicting interests.

Auteurs

Yingying Han (Y)

Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, Frankfurt 60590, Germany; Special Key Laboratory of Oral Diseases Research, Higher Education Institutions of Guizhou Province, Zunyi Medical University, Zunyi 563006, Guizhou, China; School of Stomatology, Zunyi Medical University, Zunyi 563006, Guizhou, China.

Arnaud Huard (A)

Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, Frankfurt 60590, Germany.

Javier Mora (J)

Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, Frankfurt 60590, Germany; Faculty of Microbiology, University of Costa Rica, San José 2060, Costa Rica.

Priscila da Silva (P)

Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, Frankfurt 60590, Germany; Translational Medicine and Pharmacology (TMP), Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Frankfurt 60590, Germany.

Bernhard Brüne (B)

Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, Frankfurt 60590, Germany; Translational Medicine and Pharmacology (TMP), Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Frankfurt 60590, Germany; Frankfurt Cancer Institute, Goethe-University Frankfurt, Frankfurt 60596, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt, Germany.

Andreas Weigert (A)

Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, Frankfurt 60590, Germany; Frankfurt Cancer Institute, Goethe-University Frankfurt, Frankfurt 60596, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt, Germany. Electronic address: weigert@biochem.uni-frankfurt.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH